Видео ютуба по тегу Curevac

Why is Germany's CureVac vaccine just 48% effective? | Covid-19 Special
Why is Germany's CureVac vaccine just 48% effective? | Covid-19 Special
CureVac is focusing on mRNA cancer vaccines, CFO says
CureVac is focusing on mRNA cancer vaccines, CFO says
CureVac fails in pivotal COVID-19 vaccine trial
CureVac fails in pivotal COVID-19 vaccine trial
mRNA will play a part in pandemic preparedness for the future, CureVac CEO says
mRNA will play a part in pandemic preparedness for the future, CureVac CEO says
CureVac hopes to utilize innovations in mRNA to transform the medicines of today
CureVac hopes to utilize innovations in mRNA to transform the medicines of today
CureVac: About mRNA technology
CureVac: About mRNA technology
CureVac CEO on the company's IPO and Covid-19 vaccine research
CureVac CEO on the company's IPO and Covid-19 vaccine research
CureVac strikes COVID vaccine alliance with Bayer
CureVac strikes COVID vaccine alliance with Bayer
Enough Pharma Capacity to Vaccinate World by End of 2021: CureVac CEO
Enough Pharma Capacity to Vaccinate World by End of 2021: CureVac CEO
Spotlight on CureVac – the RNA people
Spotlight on CureVac – the RNA people
CureVac working on a second generation vaccine to combat Covid variants, CEO says
CureVac working on a second generation vaccine to combat Covid variants, CEO says
CureVac withdraws mRNA Covid vaccine application in Europe
CureVac withdraws mRNA Covid vaccine application in Europe
Curevac: Fokus auf Forschung und Kostensenkung - Gewerbesteuer News
Curevac: Fokus auf Forschung und Kostensenkung - Gewerbesteuer News
„Die RNA-Revolution“ – Dr. Ingmar Hoerr (CureVac AG, Tübingen)
„Die RNA-Revolution“ – Dr. Ingmar Hoerr (CureVac AG, Tübingen)
Ocular Delivery of mRNA - Patrick Baumhof, CureVac AG
Ocular Delivery of mRNA - Patrick Baumhof, CureVac AG
Обзор IPO компании CureVac/SharesPro
Обзор IPO компании CureVac/SharesPro